U.S. Stock Market Midday Update
Soligenix fell 7.29%, with increased trading volume. Based on recent important news:
<ol>
<li>
On August 6, Soligenix's financial report showed a net income of negative, with a basic earnings per share of -$0.77, leading to a 7.29% drop in stock price.
</li>
<li>
On August 5, Soligenix's product revenue fell short of expectations, raising market concerns about its future growth, further depressing the stock price.
</li>
<li>
On August 7, International Business Settlement's stock price rose 30.54%, attracting market attention and diverting investment interest away from Soligenix.
</li>
</ol>
Stocks with High Trading Volume in the Industry
Gilead Sciences rose 9.01%, with a trading volume of $760 million. Based on recent important news:
<ol>
<li>
On August 8, Gilead Sciences released its Q2 2025 financial report, showing a 2% year-over-year increase in total revenue to $7.1 billion, in line with market expectations, with a pre-market stock price increase of 2.9%.
</li>
<li>
On August 8, Gilead Sciences raised its full-year revenue and earnings guidance, expecting adjusted earnings per share to be between $7.95 and $8.25, higher than previously expected.
</li>
<li>
On August 9, Truist upgraded Gilead Sciences' rating from hold to buy and raised the target price from $108 to $127, with the stock price increasing by 8.3%.
</li>
</ol>
Forty Pharmaceuticals fell 2.06%, with a trading volume of $652 million. Based on recent key news:
<ol>
<li>
On August 8, Forty Pharmaceuticals' VX-993 failed to show significant pain relief effects in Phase II clinical trials, leading to an 18.8% drop in stock price.
</li>
<li>
On August 7, board member BRUCE SACHS made significant internal purchases, showing confidence in the company's future.
</li>
<li>
On August 6, analysts from RBC Capital and Scotiabank lowered the target price for Forty Pharmaceuticals, from $430 to $405 and from $442 to $438, respectively.
</li>
</ol>
Natera rose 11.03%, with increased trading volume. Based on recent important news:
<ol>
<li>
On August 8, Natera reported record quarterly revenue and raised its annual revenue and gross margin guidance, driving the stock price up by 11.03%.
</li>
<li>
On August 8, Natera's short interest ratio decreased by 41.44%, boosting market confidence in the company's prospects.
</li>
<li>
On August 8, multiple institutions raised Natera's target price, further enhancing market sentiment.
</li>
</ol>
Stocks with High Market Capitalization in the Industry
AbbVie rose 0.10%, with increased trading volume. Based on recent important news:
<ol>
<li>
On August 8, AbbVie raised its full-year guidance, with significant growth in Skyrizi in the psoriasis and IBD fields, boosting market confidence and increasing stock price
</li>
<li>
On August 6, AbbVie acquired Gilgamesh Pharmaceuticals to expand its market for mental disorder medications and enhance the company's competitiveness.
</li>
<li>
On August 5, AbbVie set a sales target of $24 billion, with no significant patent cliffs in the coming years, and market expectations are optimistic
</li>
</ol>

SNGX

Soligenix fell 7.29%; Gilead Sciences rose 9.01%, with a trading volume of USD 760 million; Fortress Biotech fell 2.06%, with a trading volume of USD 652 million; Natera rose 11.03%, with a trading volume of USD 334 million; AbbVie rose 0.10%, with a market capitalization of USD 351.6 billion

U.S. Stock Market Midday Update: Soligenix down 7.29%